William Wood, MD, associate professor of medicine in the division of hematology, is leading the development of a national COVID registry for Hematologic Malignancy.
“The intent of the registry is to make data publicly available for health care providers through visualizations and reports, updated regularly,” said Wood, who serves as chair of the American Society of Hematology Research Collaborative Data Hub Oversight Group.
“Providers from all over the world are contributing information about patients with underlying blood cancers who have had a COVID infection, including basic demographics, hematologic malignancy characteristics, information about the COVID infection and outcomes, and impact on treatment.”
To date, 163 cases have been reported, and Wood expects the resource to continue to grow. The registry will also be expanded to capture information about underlying non-malignant hematologic diseases, and hematologic complications of COVID-19 infection, such as coagulopathy and thrombosis, irrespective of whether or not there was an underlying hematologic condition.